Browse By: Country ι Category ι Publisher ι Tag

Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors

Pages » 301
Published By » La Merie Publishing
Price » $2092
In stock
View Report Details
Description

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets: Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) G-CSF & GM-CSF Thrombopoietin & Thrombopoiesis Stimulating Agents Interferon Insulin Coagulation Factors Human Growth Hormone (hGH) FSH, hCG and LH: Therapeutic Pro... Click here for more details


Oncology Pipeline Database: 6-Month Subscription
Oncology Pipeline Database: 6-Month Subscription Product description Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and
Published Date: Feb 2010
Price: $1544
Oncology Pipeline Database: 1-Year Subscription
Oncology Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R
Published Date: May 2010
Price: $2316
Flat-Rate Subscription to La Merie Reports with 24/7 Online Access
Subscription to this product provides online access during one year to all reports published by La Merie and available in the online store during the subscription. Among La Merie reports are more than 100 Competitor Analysis reports as well as a growing number of Brief and Full Reports. La Merie r
Published Date: Jun 2010
Price: $5146
R&D Drug Pipeline Database: 1-Year Subscription
R&D Drug Pipeline Database: 1-Year Subscription Product description Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mecha
Published Date: Aug 2010
Price: $7719
R&D Drug Pipeline Database: 2-Months Subscription
R&D Drug Pipeline Database: 2-Months Subscription Product description Subscription to La Meries proprietary R&D Drug Pipeline Database provides online access to more than 12,000 project entries in all therapeutic areas and product categories. Each project is specified for its Target or Mec
Published Date: Aug 2010
Price: $2573
Antibody Pipeline Database: 1-Year Subscription
Subscription to La Meries proprietary Antibody Pipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase.
Published Date: Nov 2010
Price: $1544
Therapeutic Protein Pipeline Database: 1-Year Subscription
Subscription to La Merie’s proprietary Therapeutic Protein Pipeline Database provides online access to more than 1,700 project entries for therapeutic proteins on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area a
Published Date: Feb 2011
Price: $1544
RNA Therapeutics Pipeline Database: 1-Year Subscription
RNA Therapeutics Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary RNA Therapeutics Pipeline Database provides online access to RNA Therapeutics on the market and in research & development. RNA Therapeutics include the classes of antisense,
Published Date: Mar 2011
Price: $772
Vaccine Pipeline Database: 1-Year Subscription
Vaccine Pipeline Database: 1-Year Subscription Product description Subscription to La Merie’s proprietary Vaccine Pipeline Database provides online access to more than 1,200 project entries for prophylactic and therapeutic vaccines on the market and in research & development. Eac
Published Date: Oct 2011
Price: $1287
Competitor Analysis: Targeted Therapy of Hepatitis C
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to
Published Date: Aug 2011
Price: $772

 


 

Related News

New Innovations in Optics LED
New innovations in the field of lasers and optics have introduced high density white LED light engines for OEM fiber optic illumination. White light LEDs are rapidly becoming the most preferred source for light guide illumination in several technical applications which were once ruled by HID lamps and tungsten halogen. White LEDs offer operational advantages and substantial cost. LumiBright™ delivers up to 4000 lumens into the light guide. LumiBright have no additional optics and couple
Date: Dec 18

‘Fluctuations in Air Freight Impacts Pharma Supply Chains’
Air freight has been considered to be imperative to the pharmaceutical industry more so as supply chains take on a more complex shape. The Life Science and Pharmaceutical conference held in London on Tuesday stressed upon this very fact. Emerging trends such as healthcare at home, increasing clinical trials across the globe, and advanced therapies as well as companion diagnostics have tremendously changed the pharmaceutical industry, according to David Spillet, key account director at World C
Date: Dec 17

Two AC/DC Drivers Launched by ON
On Semiconductor has recently expanded their product line for NCL3008x by launching two new series of offline AC-DC drivers with Power Factor Correction. Their new line of semiconductors includes the new NCL30085/86/88/30. The NCL30030 widens the existing solutions which support higher power topologies. Their primary purpose would be in high performance LED lighting applications. The new line of PFC drivers are said to be small, robust, and flexible. Three of them use a PF corrected algorithm
Date: Dec 17

Different Prospects of New Nuclear Power
Nuclear energy was once promised as the world’s leading source to provide cheap and safe electrical power. However, The United States has led the way in nuclear research due to government finance and support. Some analysts also claimed that electricity would go meterless in the future.   Nevertheless, things did not turn out as decided due to nuclear waste accumulation, accidents, and safety problems, and most of all – rising costs. Despite these problems, growth in nuclear p
Date: Dec 17

Drop in Oil Prices sets off Alarm Bells in Producers and Shareholders
The well-publicized drop in oil prices this week has been celebrated by the masses all over the world as an answer to years of demands. However, the picture is far from rosy on the other side, as oil exporters and shareholders reacquaint themselves with a sub-$60 per-barrel pricing after a considerable hiatus. Increasing amounts of oil production from countries outside the OPEC (Organization of the Petrol Exporting Countries) is loosening OPEC’s stranglehold over the global petroleum ma
Date: Dec 16

Chinese Construction Shares Rise on Stimulus Bets
For the second consecutive day, China’s stocks have risen, led by railway and construction companies. Their growth has been based on the speculation that the government will take improved steps to support economic growth. China Railway Group Ltd. and China State Construction Engineering Corp. gained more than 7 per cent, enough to lead the rise for infrastructure related companies. Meanwhile, Premier Li Keqiang is visiting Kazakhstan to forge a Silk Road Fund that could finance the buil
Date: Dec 15

Citigroup Charges Investors with US$2.7 Billion for Legal Expenses
Citigroup gave its investors a surprise with its 4th quarter results on Tuesday, with an expected US$2.7 billion legal charge associated with multiple investigations. Citigroup has been discussing for settlement with banking regulators and federal prosecutors over a series of investigations connected to possible manipulation in the lax anti-money-laundering controls and the currency market. The 4th quarter charge also reveals the expected cost of a separate inquiry about the role Citigroup an
Date: Dec 10

After Louisiana-Pacific’s Downgrade - What’s next in the Building and Construction Products Industry?
Louisiana-Pacific Corporation was downgraded by the DA Davidson research firm last Friday from a status of “Buy” to a “Neutral” rating, i.e. LPX 0%. RBC Capital had struck a similar rating a few days earlier. It changed its rating from ‘Sector Perform’ to ‘Underperform’ - where the price target was set as $13.00 per share. These implications apply a downside potential of 22 percent from the present price (as of December 8) of $16.85 per share. 
Date: Dec 09

Southern Company Got Warning from State Monitor on Ga. Nuclear Plant Costs
State monitors has warned Southern Co. that building a multi-billion dollar nuclear plant in Georgia without having a comprehensive construction schedule could cause financial penalties. A report was filed by an analyst and an engineer working for state regulators. They supervise the elevation of two new reactors situated at Plant Vogtle in eastern Georgia. The warning was mentioned in that report. The Public Service Commission has notified for at least two years that Georgia Power, a subs
Date: Dec 08

India to Export Carabeef to Russia
According to some recent talks between India’s (APEDA) and phyto-sanitary watchdog Rosselkhoznadzor, Russia has permitted the imports of buffalo meat (carabeef) from India.  This act falls under the Ministry of Commerce and Industry of India. The move is placed a few days ahead of the Russian President’s visit to India. Rosselkhoznadzor in association with the Ministry of Agriculture of Kazakhstan has involved Indian exporters on its buffalo meat import list.  Compani
Date: Dec 08

Upcoming Reports

Biopharmaceutical Licensing Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
The biopharmaceutical industry is focusing on the growing complexity of licensing deals in order to secure marketing and commercialization rights within partnership deals. The major challenge faced by the biopharmaceutical licensing market is asymmetry between licensor and licensees. The biopharma
Published By: Transparency Market Research
Price: $4795
US Biopharmaceutical Market - Global Industry Size, Market Share, Smart Trends, Analysis And Forecast, 2012 - 2018
Biopharmaceuticals are medical drugs which are produced with the help of biotechnology. The US is the largest market for biopharmaceuticals and is the leader in terms of revenue, by a substantial margin. The biopharmaceutical market can be classified based on the class of the medical drug into r
Published By: Transparency Market Research
Price: $4795
Orthopedic Bone Material (Cement and Casting) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
Artificial joints have been anchored with bone cements for more than half a century. Bone cement plays the important role of an elastic zone by filling the space between the prosthesis and the bone. The necessity of bone cement is supported by the fact that the human hip is acted on by 10-12 tim
Published By: Transparency Market Research
Price: $4595
Single-Use Technologies For Biopharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Single use technologies involve single-use or disposable products. Such products are usually made of plastics or its derivatives such as polyamides, polycarbonates, polyethylene, polyvinyl chloride and various others. These products are becoming popular in the biopharmaceutical applications as the
Published By: Transparency Market Research
Price: $4795